Labcorp Holdings Total Cost of Revenue increased by 0.0% to $2.52B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.3%, from $2.40B to $2.52B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 5.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.58B | $2.68B | $328.20M | $2.67B | $1.98B | $1.98B | $2.13B | $2.19B | $2.19B | $2.21B | $2.21B | $2.28B | $2.29B | $2.38B | $2.43B | $2.40B | $2.48B | $2.54B | $2.52B | $2.52B |
| QoQ Change | — | +3.9% | -87.7% | +712.5% | -25.7% | +0.0% | +7.6% | +2.6% | +0.2% | +0.6% | +0.3% | +3.0% | +0.7% | +3.6% | +2.3% | -1.5% | +3.5% | +2.3% | -0.6% | +0.0% |
| YoY Change | — | — | — | — | -23.1% | -26.0% | +549.5% | -18.0% | +10.7% | +11.4% | +3.8% | +4.2% | +4.7% | +7.8% | +10.0% | +5.2% | +8.1% | +6.8% | +3.7% | +5.3% |